MIF

MIF antagonist is an inhibitor of the dopachrome tautomerase activity of MIF in vitro (IC50 = 7 M) and in cells (IC50 = 25 M).

(±)-CPSI-1306 is an orally available antagonist of macrophage migration inhibitory factor (MIF).

(E/Z)-BCI (NSC 150117) is a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory activities. (E/Z)-BCI attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting the NF-κB pathway.

BTZO-1 is an activator of the glutathione S-transferase Ya subunit (GST Ya) gene ARE by interacting with MIF.

BMY-25551 is a potent Mitomycin A analogue, exhibiting 8 to 20 times greater cytotoxicity compared to Mitomycin C in murine and human tumor cell lines. This compound is primarily investigated as an anticancer agent and shows potential in research related to cancer therapies and hematologic suppression. Its enhanced efficacy makes BMY-25551 a valuable tool for exploring mechanisms of tumor cell inhibition.

MIF-IN-1 is a potent inhibitor of macrophage migration inhibitory factor (MIF), with a reported pIC50 of 6.87. This compound is designed to selectively inhibit MIF activity, which plays a critical role in various inflammatory and immune responses. MIF-IN-1 is suitable for research applications focused on inflammation, autoimmune diseases, and cancer biology, providing valuable insights into MIF-mediated pathways.

RGB097 is a potent inhibitor of D-dopachrome tautomerase (D-DT), demonstrating an IC50 value of 0.5 µM. This compound exhibits significant biological activity and has potential applications in cancer research, particularly in elucidating the role of D-DT in oncogenesis and tumor progression.

MIF-IN-5 is a potent and reversible inhibitor of macrophage migration inhibitory factor (MIF), exhibiting a competitive mechanism of action. With an IC50 of 4.8 μM and a Ki value of 3.3 μM, it effectively disrupts MIF's biological activity. This compound is valuable for research applications involving inflammation, immune response modulation, and potential therapeutic strategies targeting various diseases associated with MIF dysregulation.

HTS05585 is a selective inhibitor of macrophage migration inhibitory factor (MIF), demonstrating a Kd value of 0.29 μM via microscale thermophoresis and 0.32±0.01 μM confirmed by isothermal titration calorimetry. This compound effectively inhibits the release of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, from LPS-stimulated macrophages. HTS05585 is a valuable tool for studying inflammation-related diseases, particularly in the context of sepsis research.

TE-11 is a potent MIF tautomerase inhibitor, exhibiting an IC50 value of 5.63 μM. This compound effectively ameliorates CD-like colitis and reduces migration of MIF-induced eosinophils and neutrophils. Additionally, TE-11 prevents M1 polarization and the associated metabolic reprogramming, making it a valuable tool for research in inflammatory and autoimmune disorders.

4-IPP (4-Iodo-6-phenylpyrimidine) is a selective suicide substrate and irreversible inhibitor targeting macrophage migration inhibitory factor (MIF). This compound significantly impedes MIF activity, making it a valuable tool for research into inflammatory processes, cancer progression, and immune response modulation. Its ability to inhibit MIF provides insights into the underlying mechanisms of various pathologies, facilitating the development of therapeutic strategies.

MIF098 is a potent macrophage migration inhibitory factor (MIF) antagonist. It effectively inhibits the proliferation, migration, and fibrosis of pulmonary smooth muscle cells, making it a valuable tool in the study of immunoinflammatory diseases. Research applications include investigating mechanisms of pulmonary disorders and exploring potential therapeutic strategies for related conditions.

ISO-92 is a selective inhibitor of migration inhibitory factor (MIF) with an IC50 of 550 nM. This compound effectively reduces inflammatory activity and demonstrates a dose-dependent inhibition of hypoxia-induced proliferation in the CCL-210 cell line. In mouse models of hypoxia, ISO-92 significantly decreases the thickness of the pulmonary vascular wall. Its unique mechanism makes ISO-92 a valuable tool for investigating inflammatory and neurological disorders.

Mitomycin A is an antitumor agent that exerts its effects primarily through DNA cross-linking, leading to inhibition of cell division. It has been shown to inhibit the spontaneous migration of mouse monocytes and reduce the production of Migration Inhibition Factor (MIF) by human lymphocytes. Mitomycin A is utilized in research focused on tumor biology and the mechanisms of cancer progression, providing insights into potential therapeutic strategies.

MD13 is a macrophage migration inhibitory factor (MIF)-directed PROTAC with a Ki of 71 nM. This compound facilitates the targeted degradation of MIF, offering potential utility in cancer research by modulating inflammatory responses associated with tumor progression. Its application may provide insights into therapeutic strategies for malignancies influenced by MIF signaling pathways.

4-CPPC is a potent and selective inhibitor of Macrophage Migration Inhibitory Factor 2 (MIF-2), demonstrating a Ki value of 33 µM. This compound exhibits reversible inhibition, showcasing a notable selectivity over MIF-1 with a Ki value of 431 µM. 4-CPPC is valuable for research applications aimed at elucidating the role of MIF-2 in inflammatory responses and other pathological conditions, making it a critical tool for studying MIF-related signaling pathways.

RDR 03785 is a covalent inhibitor of Macrophage Migration Inhibitory Factor (MIF), exhibiting an IC50 of 0.36 μM. This compound demonstrates significant biological activity in modulating MIF-related pathways, making it a valuable tool in the study of inflammatory diseases and immune response regulation. Research applications include exploring MIF's role in various pathophysiological processes, as well as potential therapeutic interventions targeting MIF.

MKA031 is a non-competitive inhibitor of macrophage migration inhibitory factor (MIF) with an IC50 value of 1.7 μM. This compound disrupts the interaction between MIF and AIF, impedes MIF nuclear translocation, and interferes with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced cell death. MKA031 is particularly useful for research applications focused on chronic hepatitis C virus infection and related cellular pathways.

R110 is a potent competitive inhibitor of macrophage migration inhibitory factor 2 (MIF2) tautomerase, exhibiting an IC50 of 15 μM. This compound is valuable for research into cancer biology, specifically in mechanisms related to tumor progression and immune modulation. By targeting MIF2, R110 offers potential insights into therapeutic strategies for cancer treatment.

MIF2-IN-1 is a potent inhibitor of the MIF2 tautomerase, exhibiting an IC50 of 1.0 μM. This compound effectively suppresses the proliferation of non-small cell lung cancer cells by inducing cell cycle arrest through the deactivation of the MAPK signaling pathway. MIF2-IN-1 is a valuable tool for researching cancer biology and therapeutic strategies in oncology.

MIF-IN-4 hydrochloride is a potent inhibitor of macrophage migration inhibitory factor (MIF), with an affinity corresponding to a pIC50 of 5.01-6. MIF is a crucial cytokine involved in regulating macrophage migration and immune responses. This compound is valuable for research applications focused on inflammation, immune modulation, and related pathways.

MIF-IN-6 is a potent inhibitor of macrophage migration inhibitory factor (MIF), exhibiting an IC50 of 1.4 μM and a Ki value of 0.96 μM. This compound effectively attenuates MIF-induced ERK phosphorylation and inhibits the proliferation of A549 cells, making it valuable for studies related to cancer biology and inflammation. Its mechanism of action positions MIF-IN-6 as a significant tool for exploring MIF-related pathways and potential therapeutic interventions.